No.3
obicetrapib's ultimate value will be determined by PREVAIL Study.
PREVAIL Study（NCT05202509）
・Condition : Atherosclerotic Cardiovascular Disease who are not adequately controlled
despite maximally tolerated lipid-lowering therapy.
• Completion: 2026-11
• Enrollment: 9,541
返信
投資の参考になりましたか？
